Navigation Links
MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
Date:12/15/2008

Live Broadcast on December 18, 2008 at 9 a.m. Eastern Time

VALENCIA, Calif., Dec. 15 /PRNewswire-FirstCall/ --MannKind Corporation (Nasdaq: MNKD) will host a live broadcast to review clinical results from its final two Phase 3 studies of AFRESA(TM), the company's ultra rapid acting, inhaled insulin product, at 9 a.m. Eastern Time on Thursday, December 18, 2008.

To participate in the live call by telephone, please dial (888) 677-5721 or (210) 839-8507. Those interested in viewing the live webcast via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com.

A telephone replay of the call will be accessible for approximately fourteen days following completion of the call by dialing (800) 873-5860 or (203) 369-3996. A replay will also be available on MannKind's website for fourteen days.

About AFRESA

Afresa is an ultra rapid acting inhaled insulin product that has completed Phase 3 trials. The pharmacokinetic profile of Afresa sets it apart from all other insulin products. The large surface area of the lung provides unique access to the circulatory system. The pH-sensitive Afresa particles immediately dissolve upon contact with the lung surface, releasing insulin monomers that rapidly enter the bloodstream. It achieves peak insulin levels within 12-14 minutes of administration, effectively mimicking the release of meal-time insulin observed in healthy individuals, but which is absent from patients with diabetes.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercializatio
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
2. MannKind Addresses Pfizers Announcement Regarding Exubera
3. PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies
4. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains
6. Successful Results for Mymetics Corporations Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations
7. National Jewish Health and Roche Diagnostics Corporation Reach Agreement to Pursue Environmental Molecular Diagnostics Opportunities
8. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
9. Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
10. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
11. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... N.J. , June 18, 2013  Actavis, Inc. (NYSE: ... Actavis") has filed with the U.S. Securities and Exchange Commission ... Actavis, proposed acquisition of Warner Chilcott plc (NASDAQ: ... of Actavis and Warner Chilcott (the "Form S-4"). ... and Warner Chilcott have entered into a definitive ...
(Date:6/18/2013)... June 18, 2013  Recent regulatory and budget challenges ... Education groups at large pharmaceutical companies to effectively educate ... effective use of their new products. With the pressure ... is crucial that these "Med Ed" groups ... To address the changes that are transforming the ...
(Date:6/18/2013)... LEANDRO, Calif. , June 18, 2013  Cataracts ...  According to the American Association of Ophthalmology, aging is ... a clouding of the eye,s natural lens. 22 million ... 2020, as Baby Boomers continue to age, that number ... high tech world of iPhones, iPads, smart-phones and computers, ...
Breaking Medicine Technology:Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2New Vision Hope For Millions Undergoing Cataract Surgery 2New Vision Hope For Millions Undergoing Cataract Surgery 3
... LLC ("Deston") announced today that it is currently exploring its ... Otic Solution ("Auralgan") by the Federal Government and that it ... product. "Despite the recent actions by the ... effective treatment for ear pain and inflammation," said David Preston ...
... N.J., Feb. 25, 2011 ConvaTec, a world-leading developer ... hospital care, today announced a new appointment to its ... Senior Vice President and Chief Quality Officer for ConvaTec ... member of the ConvaTec Executive Committee. McNally will be ...
Cached Medicine Technology:Deston Therapeutics Stands By Safety and Efficacy of Auralgan After FDA Action 2Deston Therapeutics Stands By Safety and Efficacy of Auralgan After FDA Action 3Deston Therapeutics Stands By Safety and Efficacy of Auralgan After FDA Action 4
(Date:6/18/2013)... Palo Alto has taken yet another step ... with its recent major long-term solar power commitment. , ... electric power purchase agreements , which together will result in ... photovoltaic electric power per year, which is the equivalent of ... enough power to supply all 65,000+ Palo Alto residents---and then ...
(Date:6/18/2013)... Sun Buick GMC, Moosic, is sponsoring the hole-in-one contest at ... on Thursday, June 20, at Irem Country Club, Dallas, Pennsylvania. ... Verano and will go to the lucky golfer at the ... , The MFHS golf tournament is open to all interested ... crew team for 18 holes. The fee is $125 per ...
(Date:6/18/2013)... 2013 Internationally acclaimed plastic surgeon, ... thebestbreast.com, showcasing his unique approach to breast augmentation. ... his surgical method and highlights the results of ... website, Dr. Tebbetts compares his breast augmentation method ... Tebbetts’ method does not necessitate the use drains, ...
(Date:6/18/2013)... Hospitals Case Medical Center clinical researchers have launched ... which will evaluate the ability of a patient,s ... end stage peripheral arterial disease (PAD). , ... Surgery at University Hospitals Case Medical Center,s Harrington ... at Case Western Reserve University School of Medicine, ...
(Date:6/18/2013)... signaling network between two previously unconnected proteins, exposing a ... growth at its starting point. , A team led ... Cancer Center reported the tie between epidermal growth factor ... a protein vital to the first step in DNA ... . , "MCM7 overexpression marks cell proliferation and is ...
Breaking Medicine News(10 mins):Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 2Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 3Health News:Internationally Acclaimed Breast Augmentation Expert Announces the Launch of His New Website 2Health News:UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation 2Health News:Scientists catch EGFR passing a crucial message to cancer-promoting protein 2
... images offers the possibility of using magnetic resonance imaging ... path of many degenerative brain diseases, report scientists at ... of California, San Francisco. The technique, developed by ... Bruce Miller, MD, clinical director of the UCSF Memory ...
... , TUESDAY, April 10 (HealthDay News) -- Black people with ... cardiac death than whites or other racial groups who suffer ... was true regardless of blacks, other risk factors, such as ... Researchers examined 533 black and 8,660 non-black patients ...
... passed the motor vehicle administration,s vision test may not mean ... found that the frequency and distance at which drivers with ... night was severely reduced, even when the drivers have passed ... are very common and lots of people with these conditions ...
... in low- and middle-income countries, and there is an ... help tackle the disease, states an analysis in CMAJ ... more people than HIV/AIDS, tuberculosis and malaria combined. The ... rise through 2030 of 82% in low- and lower-income ...
... San Diego, CA - The American Society of Pediatric ... April 22, during the 2012 Combined Otolaryngology Spring Meetings ... in San Diego, CA. During the ASPO meeting, ... scientific sessions featuring expert panelists will be presented focusing ...
... Doheny HealthDay Reporter , MONDAY, April 9 ... protect against repeat heart attacks, strokes or other cardiovascular ... surprised at these findings because I assumed that there ... Dr. Seung-Kwon Myung, chief of the carcinogenesis branch of ...
Cached Medicine News:Health News:New MRI technique may predict progress of dementias 2Health News:High Blood Pressure May Be Especially Lethal for Blacks 2Health News:Can a standard vision test predict nighttime driving performance? 2Health News:Scientific session and new research highlights 2Health News:Omega-3 Supplements No Help Against Repeat Heart Trouble: Review 2Health News:Omega-3 Supplements No Help Against Repeat Heart Trouble: Review 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: